Table 1.
Comparison of demographic, clinical, and ECG characteristics of the two cohorts
| Both cohorts | Cohort zero PpV1 N = 3,405 |
Cohort DTNPV1 N = 3,413 |
P-value | |
|---|---|---|---|---|
| Age (SD), y | 58.3(16.2) | 58.0(16.2) | 58.5(16.1) | 0.203 |
| Female, n (%) | 3,046(44.7) | 1,520(44.6) | 1,526(44.7) | 0.953 |
| Referred by cardiologist, n(%) | 1,143(16.8) | 623(18.3) | 520(15.2) | <0.0001 |
| Ordered in Intensive Care Unit or ED, n(%) | 119(1.8) | 46(1.4) | 73(2.4) | 0.013 |
| Ordered in Intensive Cardiac Care Unit, n(%) | 33(0.5) | 11(0.3) | 22(0.6) | 0.056 |
|
| ||||
| Coronary heart disease, n(%) | 984(14.4) | 364(10.7) | 620(18.2) | <0.0001 |
| History of myocardial infarction, n(%) | 361(5.3) | 126(3.7) | 235(6.9) | <0.0001 |
| History of CABG, n(%) | 136(2.0) | 44(1.3) | 92(2.7) | <0.0001 |
| Heart failure, n(%) | 900(13.2) | 273(8.0) | 627(18.4) | <0.0001 |
| New Implantable Cardioverter Defibrillator, n(%) | 223(3.3) | 68(2.0) | 155(4.5) | <0.0001 |
| New Pacemaker, n(%) | 168(2.5) | 77(2.3) | 91(2.7) | 0.281 |
| Chronic obstructive pulmonary disease, n(%) | 397(5.8) | 156(4.6) | 241(7.1) | <0.0001 |
| Chronic liver disease, n(%) | 246(3.6) | 123(3.6) | 123(3.6) | 0.985 |
| Diabetes mellitus, n(%) | 1,176(17.3) | 478(14.0) | 697(20.4) | <0.0001 |
| Chronic kidney disease, n(%) | 80(1.2) | 23(0.7) | 57(1.7) | <0.0001 |
|
| ||||
| Ever prescribed any medication at OHSU, n(%) | 6,174(90.6) | 3,000(88.1) | 3,174(93.0) | <0.0001 |
| ACE inhibitors/ARBs, n(%) | 2,040(29.9) | 894(26.3) | 1,146(33.6) | <0.0001 |
| Antiarrhythmic drugs, n(%) | 215(3.2) | 89(2.6) | 126(3.7) | 0.011 |
| Anticoagulants, n(%) | 831(12.2) | 412(12.1) | 419(12.3) | 0.824 |
| Anti-platelets/ASA, n(%) | 2,695(39.5) | 1,158(34.0) | 1,537(45.0) | <0.0001 |
| Beta blockers, n(%) | 2,491(36.5) | 1,073(29.8) | 1,524(43.2) | <0.0001 |
| Calcium channel blockers, n(%) | 1,077(15.8) | 457(13.4) | 620(18.2) | <0.0001 |
| Diuretics, n(%) | 1,885(27.7) | 827(24.3) | 1,058(31.0) | <0.0001 |
| Nitrates/hydralazine, n (%) | 395(5.8) | 139(4.1) | 256(7.5) | <0.0001 |
| Statins, n(%) | 2,349(34.5) | 1,045(30.7) | 1,304(38.2) | <0.0001 |
| Any CV condition/risk factor/meds/referral, n(%) | 4,803(70.5) | 2,215(65.1) | 2,588(75.8) | <0.0001 |
|
| ||||
| P-prime V1 amplitude, μV(SD) | - | 0 | −119.5(19.6) | <0.0001 |
| Heart rate, bpm(SD) | 81.7(21.6) | 78.6(22.7) | 84.7(20.0) | <0.0001 |
| PR interval, n (SD) | 147.0(52.4) | 135.0(64.3) | 159.0(32.7) | <0.0001 |
| QTc interval, n (SD) | 448.1(39.0) | 441.8(39.5) | 454.5(37.4) | <0.0001 |
SD=standard deviation; ED=Emergency Department; ACE=angiotensin-converting-enzyme; ARBs = angiotensin II receptor blockers; ASA=acetylsalicylic acid.